The clinical efficacy of therapies that target some of the inhibitory mechanisms that regulate anti-tumoral CD8 function (for example, PD-1 blocking antibodies) indicates that CD8 T-cell manipulation is promising in the setting of certain types of cancer. Here, CD8A is linked to cancer.